Gene scanning of VDJH-amplified segments is a clinically relevant technique to detect contaminating tumor cells in the apheresis products of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation

Bone Marrow Transplantation

Volumn 28, Issue 7, 2001, Pages 665-672

  Lopez Perez R ^a   Garcia Sanz R ^a   Gonzalez D ^a   Balanzategui, A ^a   Chillon M C ^a   Alaejos, I ^a   Mateos, M V ^a   Caballero, M D ^a   Corral, M ^a   Orfao A ^a   Gonzalez M ^a   San Miguel, J F ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Apheresis; Gene scanning; IgH gene; IgH rearrangement; Myeloma; Transplantation

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN J CHAIN; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY;

ADULT; AGE; APHERESIS; ARTICLE; AUTOTRANSPLANTATION; CANCER REGRESSION; CANCER SURVIVAL; CELL CLONE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTAMINATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENE AMPLIFICATION; GENE REARRANGEMENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOGLOBULIN GENE; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; TECHNIQUE; TREATMENT OUTCOME; TUMOR CELL;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD COMPONENT REMOVAL; BONE MARROW PURGING; CELL COUNT; CLONE CELLS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DISEASE-FREE SURVIVAL; GENE REARRANGEMENT, B-LYMPHOCYTE, HEAVY CHAIN; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOPHENOTYPING; INTERFERONS; LIFE TABLES; MIDDLE AGED; MULTIPLE MYELOMA; MYELOMA PROTEINS; NEOPLASM CIRCULATING CELLS; PLASMA CELLS; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; SALVAGE THERAPY; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 0034748096     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703219     Document Type: Article

References (39)

1. Treatment of multiple myeloma
2. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome
3. Diagnosis, prognosis, and standard treatment of multiple myeloma
4. Peripheral blood stem cell transplants for multiple myeloma: Identification of favorable variables for rapid engraftment in 225 patients
5. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma
6. Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma
7. G-CSF alone mobilizes sufficient peripheral blood CD34+ cells for positive selection in newly diagnosed patients with myeloma
8. Leukapheresis cells of patients with multiple myeloma collected after mobilization with chemotherapy and G-CSF do not bear Kaposi's sarcoma associated herpesvirus DNA
9. The detection of contaminating clonal cells in apheresis products is related to response and outcome in multiple myeloma undergoing autologous peripheral blood stem cell transplantation
10. Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients
11. Monoclonal plasma cells in the blood stem cell harvest from patients with multiple myeloma are associated with shortened relapse-free survival after transplantation
12. Detection of malignant B cells in peripheral blood stem cell collections after chemotherapy in patients with multiple myeloma
13. Detection of monoclonal plasma cells in the peripheral blood stem cell harvests of patients with multiple myeloma
14. Detection of peripheral blood plasma cells as a predictor of disease course in patients with smouldering multiple myeloma
15. The relationship between monoclonal myeloma precursor B cells in the peripheral blood stem cell harvests and the clinical response of multiple myeloma patients
16. Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma
17. Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma
18. Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts
19. High-dose sequential chemoradiotherapy in multiple myeloma: Residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting
20. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: Positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells
21. Leukapheresis products in multiple myeloma: Lower tumor load after mobilization with cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) compared with G-CSF alone
22. Minimal residual disease after bone marrow transplantation for multiple myeloma: Evidence for cure in long-term survivors
23. Myeloma cell contamination of peripheral blood stem cell grafts in patients with multiple myeloma treated by high-dose therapy
24. Heteroduplex PCR analysis of rearranged T cell receptor genes for clonality assessment in suspect T cell proliferations
25. Proposed guidelines for protocol studies. I. Introduction. II. Plasma cell myeloma. 3. Chronic lymphocytic leukemia. IV. Chronic granulocytic leukemia
26. Heteroduplex PCR analysis of rearranged immunoglobulin genes for clonality assessment in multiple myeloma
27. Autologous peripheral blood stem cell transplantation for multiple myeloma: A report of 259 cases from the Spanish Registry
28. Minimal number of circulating CD34+ cells to ensure successful leukapheresis and engraftment in autologous peripheral blood progenitor cell transplantation
29. Remission status defined by immunofixation vs electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients
30. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation
31. High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma
32. Heteroduplex analysis of VDJ amplified segments from rearranged IgH genes for clonality assessments in B-cell non-Hodkin's lymphoma. A comparison between different strategies
33. Molecular and clinical remissions in multiple myeloma: Role of autologous and allogeneic transplantation of hematopoietic cells
34. Clinical and molecular follow-up by amplification of the CDR-III IgH region in multiple myeloma patients after autologous transplantation of hematopoietic CD34+ stem cells
35. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma
36. Double high-dose chemoradiotherapy with autologous stem cell transplantation can induce molecular remissions in multiple myeloma
37. Contamination of peripheral blood by monoclonal B cells following treatment of multiple myeloma by high-dose chemotherapy
38. Clinical utility of immunoglobulin heavy chain gene rearrangement identification for tumour cell detection in multiple myeloma
39. Molecular detection of clonally rearranged cells in peripheral blood progenitor cell harvests from multiple myeloma patients